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VEGF-A Neutralization Suppresses Experimental
Abdominal Aortic Aneurysm (AAA) Formation
Keith J. Glover, Baohui Xu, Yasunori Iida, Haojun Xuan,
Hiroki Tanaka, Wei Wang, Naoki Fujimura, Mary
Gerritsen, Ronald L. Dalman. Stanford University School
of Medicine, Stanford, Calif
Objectives: Aortic mural angiogenesis is a key patho-
logic feature of AAA disease. We previously reported that
VEGF-receptor 2 expression correlated with experimental
AAA progression. This study evaluated the inﬂuence of
anti-VEGF-A monoclonal antibody (mAb) therapy on
AAA formation and progression in the porcine pancreatic
elastase (PPE) infusion model in C57Bl/6J mice.
Methods: PPE-infused mice were given anti-VEGF-A
neutralizing mAb or control mAb. Aortic aneurysm
progression was evaluated via serial transabdominal in
vivo ultrasonography and histology at sacriﬁce.
Results: In control mAb-treated mice, persistent and
signiﬁcant aortic enlargement was noted beginning the
third day following PPE infusion. Anti-VEGF-A mAbFig. A and B, Mice were injected with anti-VEGF-A or control
mAb (5 mg/kg/i.p. q.o.d) beginning 3 days prior to PRE infusion
(progression, A) or 5 days following PRE infusion (regression, B).
Diameters were measured via ultrasonography. C, Aortic frozen
sections stained for medial elastin (EVG), smooth muscles (SMC
a actin), angiogenesis (CD31), and leukocytes (CD11b for
monocytes/macrophages, CD3 for T cells and B220 for B cells).
Data presented as mean +/ S.D., n¼ 5-8 per group. ACS¼ aortic
cross section. *P < .05 and **P < .01, two- or one-way ANOVA
followed by Newman-Keuls test compared to control mAb.treatment initiated 3 days prior to PPE infusion signiﬁ-
cantly attenuated PPE-induced aortic expansion. Histolog-
ically, the VEGA-A neutralization resulted in preserved
medial smooth muscles and elastin, and reduced mural
leukocyte inﬁltration and angiogenesis. Although anti-
VEGF-A mAb treatment initiated 5 days following PPE
infusion reduced mural inﬂammation, aortic diameters
continued to enlarge.
Conclusions: Anti-VEGF-A mAb prevents the initia-
tion and subsequent progression of experimental AAAs.
The mAb treatment has limited effects on existing
aneurysms.
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Endotension: Net Flow through an Endoleak
Determines its Visibility
Stuart Blackwood2, Doran Mix1, Mallory Wingate1, Ankur
Chandra1, Alan Dietzek2. 1Cardiovascular Engineering
Lab (CVEL), Division of Vascular Surgery, University of
Rochester, Rochester, NY; 2Department of Vascular
Surgery, Danbury Hospital, Danbury, Conn
Objectives: Unexplained aneurysm growth despite
multimodality imaging following EVAR is often attributed
to endotension. We tested a hypothesis that endotension
may be from a type 1a endoleak (EL) pressurizing the
aneurysm sac without net forward ﬂow, not visualized on
standard angiographic imaging.
Methods: A patient-speciﬁc aortic aneurysm phantom
was constructed of polyvinyl alcohol using 3D molding
techniques. A bifurcated stent graft was implanted and
the phantom connected to a hemodynamic simulator for
testing. Type 1a ELs were created using seven Fr catheters.
Three scenarios were studied: complete exclusion (no EL);
inﬂow with no sac outﬂow; and inﬂow with sac outﬂow.
DSA imaging was performed at 48kvP at 5fps followed
by delayed imaging (1 frame/min) over 30 minutes.
Results: With no EL, the systemic MAP (sMAP) aver-
aged 113 mmHg and Aneurysm Sac MAP (asMAP) aver-
aged 101 mmHg. (Table) With EL without outﬂow, the
sMAP averaged 116 mmHg and asMAP averaged 120
mmHg. EL ﬂow was bidirectional with no net forward
ﬂow. With EL with aneurysm sac outﬂow, the sMAP
averaged 119 mmHg and asMAP averaged 105.5 mmHg.
EL ﬂow was 39 cc/min across the EL channel. With DSA
imaging, the EL with no outﬂow was noted after >9 min
of delayed imaging.
Conclusions: Our model demonstrated a Type Ia EL
in the absence of aneurysm sac outﬂow resulting in full
pressurization of the aneurysm sac with biphasic (zero
net) ﬂow. This EL was not visible on standard contrast
DSA until >9 min. This model may serve as a ﬁrst step
in explaining both the mystery of endotension and in
vivo aneurysm sac growth with no detectable ELs using
current standard imaging modalities.
